1007881-21-1

Basic information

• Product Name: (2S,3R)-3-Methoxy-2-((Methoxycarbonyl)aMino)butanoic acid
• Synonyms: (2S,3R)-3-Methoxy-2-((Methoxycarbonyl)aMino)butanoic acid;N-(methoxycarbonyl)-O-methyl-L-threonine
• CAS NO: 1007881-21-1
• Molecular Formula: C₇H₁₃NO₅
• Molecular Weight: 191.18182
• Mol File: 1007881-21-1.mol

Chemical Properties

• Boiling Point: 339.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.209±0.06 g/cm3(Predicted)
• PKA: 3.93±0.10(Predicted)
• CAS DataBase Reference: (2S,3R)-3-Methoxy-2-((Methoxycarbonyl)aMino)butanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R)-3-Methoxy-2-((Methoxycarbonyl)aMino)butanoic acid(1007881-21-1)
• EPA Substance Registry System: (2S,3R)-3-Methoxy-2-((Methoxycarbonyl)aMino)butanoic acid(1007881-21-1)

Safety Data

• Hazardous Substances Data: 1007881-21-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoic acid is used as a pharmaceutical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its chiral nature and diverse functional groups make it a valuable building block in the development of new medications with improved efficacy and selectivity.
Used in Biochemistry Research:
In the field of biochemistry, (2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoic acid serves as a research tool to study enzyme specificity, substrate recognition, and the role of chirality in biological systems. Its unique structure allows scientists to investigate the interactions between enzymes and their substrates, leading to a better understanding of enzymatic mechanisms and the development of targeted therapies.
Used in Material Science:
(2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoic acid is utilized in material science for the development of novel materials with specific properties. Its functional groups can be exploited to create self-assembling systems, polymers, or other materials with tailored characteristics for applications in areas such as drug delivery, sensors, or nanotechnology.

Upstream product

• 4144-02-9 O-methyl-L-threonine 
• 79-22-1 methyl chloroformate 
• 2076-53-1 O-methyl-L-threonine 
• 1352212-74-8 methyl N-(methoxycarbonyl)-O-methyl-L-threoninate 
• 3373-59-9 L-threonine methyl ester 
• 1396972-31-8 (2R,3R)-2-(tert-butoxycarbonylamino)-3-methoxybutanoic acid 
• 111398-44-8 N-methoxycarbonyl-L-valine 

Downstream Products

• 1377050-38-8 methyl {(1R)-2-[(2S,4S)-2-(9-{2-[(2S)-1-{(2S,3R)-3-methoxy-2-[(methoxycarbonyl)amino]butanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate 
• 1377050-89-9 methyl {(1R)-2-[(2S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methoxybutanoyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl}-1H-imidazol-2-yl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate 

Relevant articles and documents

Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)

Curative interferon and ribavirin sparing treatments for hepatitis C virus (HCV)-infected patients require a combination of mechanistically orthogonal direct acting antivirals. A shared component of these treatments is usually an HCV NS5A inhibitor. First generation FDA approved treatments, including the component NS5A inhibitors, do not exhibit equivalent efficacy against HCV virus genotypes 1-6. In particular, these first generation NS5A inhibitors tend to select for viral drug resistance. Ombitasvir is a first generation HCV NS5A inhibitor included as a key component of Viekira Pak for the treatment of patients with HCV genotype 1 infection. Since the launch of next generation HCV treatments, functional cure for genotype 1-6 HCV infections has been achieved, as well as shortened treatment duration across a wider spectrum of genotypes. In this paper, we show how we have modified the anchor, linker, and end-cap architecture of our NS5A inhibitor design template to discover a next generation NS5A inhibitor pibrentasvir (ABT-530), which exhibits potent inhibition of the replication of wild-type genotype 1-6 HCV replicons, as well as improved activity against replicon variants demonstrating resistance against first generation NS5A inhibitors.

HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors

A matched and mixed capping SAR study was conducted on the tetracyclic indole class of HCV NS5A inhibitors to examine the influence of modifications of this region on the overall HCV virologic resistance profiles.

Fused tricyclic hepatitis virus inhibitor and application thereof

The invention belongs to the field of medical chemistry, relates to a fused tricyclic hepatitis virus inhibitor and application thereof, and particularly, provides a compound of the general formula I or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and a medicine composition containing the compounds and application of the compounds or the composition in medicine preparation. The compound has the good inhibiting activity on hepatitis C virus, meanwhile has the low toxicity on host cells, and is high in effectiveness, good in safety and likely to become the medicine for treating and/or preventing diseases relevant to HCV infection.

9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF

The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

SUBSITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS

The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I [in-line-formulae]D-M-D??(Formula I)[/in-line-formulae] useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/ and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

Benzimidazole-imidazole Derivatives

Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R′ are, each independently, —CR1R2R3, aryl, heteroaryl or heteroC4-6cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.